Skip to main content

Advertisement

SpringerLink
Log in

Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

The aims of this study were to investigate prognosis and validate prognostic models [Memorial Sloan-Kettering Cancer Center (MSKCC), International Metastatic Renal Cell Carcinoma Data Consortium (IMDC), and Japanese metastatic renal cancer (JMRC) models] in the targeted therapy era in Japanese patients with metastatic renal cell carcinoma.

Methods

We retrospectively analyzed 692 patients who were diagnosed with mRCC from January 2008 to August 2018 in the Michinoku Japan Urological Cancer Study Group database. Nivolumab as sequential therapy was widely used. Other immune checkpoint inhibitors were excluded from this study.

Results

The median overall survival (95% confident interval) in all, MSKCC favorable, intermediate, and poor risk patients was 41.0 months (33.9–46.8), not reached (63.5 to not estimable), 46.8 months (37.1–52.9), and 10.4 months (8.9–14.4), respectively. The median overall survival (95% confident interval) in IMDC favorable, intermediate, and poor risk patients was not reached (61.6 to not estimable), 47.4 months (41.4–56.5), and 11.5 (9.9–16.3), respectively. The c-index of the MSKCC, IMDC, and JMRC models calculated at mRCC diagnosis was 0.680, 0.689, and 0.700, respectively. No statistical differences were found in the c-index among the models.

Conclusion

While the real-world overall survival in Japanese patients with mRCC in the targeted therapy era improved compared to that previously reported in the cytokine era, there was no clear difference in the survival of poor risk patients between these eras. There were no differences in the superiority among the models.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373(19):1803–1813. https://doi.org/10.1056/NEJMoa1510665

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Motzer RJ, Tannir NM, McDermott DF et al (2018) Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378(14):1277–1290. https://doi.org/10.1056/NEJMoa1712126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Motzer RJ, Penkov K, Haanen J et al (2019) Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. https://doi.org/10.1056/NEJMoa1816047

    Article  PubMed  PubMed Central  Google Scholar 

  4. Rini BI, Plimack ER, Stus V et al (2019) Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. https://doi.org/10.1056/NEJMoa1816714

    Article  PubMed  PubMed Central  Google Scholar 

  5. Greef B, Eisen T (2016) Medical treatment of renal cancer: new horizons. Br J Cancer 115(5):505–516. https://doi.org/10.1038/bjc.2016.230

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. McKay RR, Bosse D, Choueiri TK (2018) Evolving systemic treatment landscape for patients with advanced renal cell carcinoma. J Clin Oncol. https://doi.org/10.1200/jco.2018.79.0253

    Article  PubMed  Google Scholar 

  7. Osawa T, Takeuchi A, Kojima T et al (2019) Overview of current and future systemic therapy for metastatic renal cell carcinoma. Jpn J Clin Oncol. https://doi.org/10.1093/jjco/hyz013

    Article  PubMed  PubMed Central  Google Scholar 

  8. Wahlgren T, Harmenberg U, Sandström P et al (2013) Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008). Br J Cancer 108(7):1541–1549. https://doi.org/10.1038/bjc.2013.119

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Naito S, Yamamoto N, Takayama T et al (2010) Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol 57(2):317–325. https://doi.org/10.1016/j.eururo.2008.12.026

    Article  CAS  PubMed  Google Scholar 

  10. Shinohara N, Obara W, Tatsugami K et al (2015) Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy. Cancer Sci 106(5):618–626. https://doi.org/10.1111/cas.12646

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20(1):289–296. https://doi.org/10.1200/jco.2002.20.1.289

    Article  CAS  PubMed  Google Scholar 

  12. Heng DY, Xie W, Regan MM et al (2013) External validation and comparison with other models of the International metastatic renal-cell carcinoma database consortium prognostic model: a population-based study. Lancet Oncol 14(2):141–148. https://doi.org/10.1016/S1470-2045(12)70559-4

    Article  PubMed  PubMed Central  Google Scholar 

  13. Heng DY, Xie W, Regan MM et al (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27(34):5794–5799. https://doi.org/10.1200/JCO.2008.21.4809

    Article  CAS  PubMed  Google Scholar 

  14. Shinohara N, Nonomura K, Abe T et al (2012) A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma. Cancer Sci 103(9):1695–1700. https://doi.org/10.1111/j.1349-7006.2012.02351.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Motzer RJ, Rini BI, McDermott DF et al (2019) Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 20(10):1370–1385. https://doi.org/10.1016/s1470-2045(19)30413-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Ishihara H, Takagi T, Kondo T et al (2020) Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy. Jpn J Clin Oncol. https://doi.org/10.1093/jjco/hyaa171

    Article  PubMed  Google Scholar 

  17. Procopio G, Verzoni E, Iacovelli R et al (2012) Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. Br J Cancer 107(8):1227–1232. https://doi.org/10.1038/bjc.2012.327

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kubackova K, Melichar B, Bortlicek Z et al (2015) Comparison of two prognostic models in patients with metastatic renal cancer treated with sunitinib: a retrospective registry-based study. Target Oncol 10(4):557–563. https://doi.org/10.1007/s11523-015-0366-9

    Article  PubMed  Google Scholar 

  19. Rini BI, Hutson TE, Figlin RA et al (2018) Sunitinib in patients with metastatic renal cell carcinoma: clinical outcome according to international metastatic renal cell carcinoma database consortium risk group. Clin Genitourin Cancer 16(4):298–304. https://doi.org/10.1016/j.clgc.2018.04.005

    Article  PubMed  PubMed Central  Google Scholar 

  20. Escudier B, Motzer RJ, Tannir NM et al (2020) Efficacy of nivolumab plus ipilimumab according to number of IMDC risk factors in checkmate 214. Eur Urol 77(4):449–453. https://doi.org/10.1016/j.eururo.2019.10.025

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Yoichi Arai, Koji Mitsuzuka, Takahiro Kojima, and Kento Morozumi for their invaluable support with data collection. And we would also like to thsank Enago (www.enago.jp) for the English language editing.

Author information

Authors and Affiliations

  1. Department of Urology, Yamagata University Faculty of Medicine, Iida-Nishi 2-2-2, Yamagata, 990-9585, Japan

    Sei Naito, Tomoyuki Kato & Norihiko Tsuchiya

  2. Department of Urology, Akita University Graduate School of Medicine, 1-1-1, Hondo, Akita, 010-8543, Japan

    Kazuyuki Numakura, Shintaro Narita & Tomonori Habuchi

  3. Department of Urology, Hirosaki University Graduate School of Medicine, 5 Zaifu-chou, Hirosaki, 0368562, Japan

    Shingo Hatakeyama, Hayato Yamamoto & Chikara Ohyama

  4. Department of Urology, Fukushima Medical University School of Medicine, 1 hikarigaoka, Fukushima, 960-1295, Japan

    Tomoyuki Koguchi, Soichiro Ogawa & Yoshiyuki Kojima

  5. Department of Urology, University of Tsukuba Graduate School of Medicine, 1-1-1 Tennodai, Tsukuba, 305-8575, Japan

    Shuya Kandori & Hiroyuki Nishiyama

  6. Department of Urology, Tohoku University School of Medicine, 1-1, Seiryo-machi, Aoba-ku, Sendai, Miyagi, 980-8574, Japan

    Yoshihide Kawasaki & Akihiro Ito

  7. Department of Urology, Miyagi Cancer Center, 47-1, Nodayama, Shiote, Medeshima, Natori, Miyagi, 981-1293, Japan

    Hisanobu Adachi & Sadafumi Kawamura

  8. Department of Urology, Iwate Medical University School of Medicine, Yahaba 2-1-1, Shiwa, Iwate, 028-3695, Japan

    Renpei Kato & Wataru Obara

Authors
  1. Sei Naito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomoyuki Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuyuki Numakura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shingo Hatakeyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomoyuki Koguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shuya Kandori
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yoshihide Kawasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hisanobu Adachi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Renpei Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shintaro Narita
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hayato Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Soichiro Ogawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Sadafumi Kawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Wataru Obara
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Akihiro Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Hiroyuki Nishiyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Yoshiyuki Kojima
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Chikara Ohyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Tomonori Habuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Norihiko Tsuchiya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sei Naito.

Ethics declarations

Conflict of interest

No author has any conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (XLSX 11 kb)

Supplementary file2 (XLSX 10 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Naito, S., Kato, T., Numakura, K. et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era. Int J Clin Oncol 26, 1947–1954 (2021). https://doi.org/10.1007/s10147-021-01979-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-021-01979-9

Keywords

Search

Navigation